Related Experiment Video
Updated: Jul 14, 2026

Analysis of Beta-cell Function Using Single-cell Resolution Calcium Imaging in Zebrafish Islets
Published on: July 3, 2018
The importance of beta-cell management in type 2 diabetes
1Munich Institute of Diabetes Research and Medical Department, Krankenhaus Munchen-Schwabing, Munich, Germany. eberhard.standl@lrz.uni-muenchen.de
Abstract:
Despite intervention with effective oral glucose-lowering agents, most patients with type 2 diabetes will experience a gradual loss of glycaemic control. Irrespective of underlying levels of insulin resistance, the progressive failure and loss of beta-cells are ultimately responsible for the onset of frank type 2 diabetes. The mechanisms responsible for loss of beta-cell function are likely to be multifactorial, but may involve toxicity because of elevated glucose and/or lipid levels, increased secretory demand because of insulin resistance, amyloid deposition and altered levels of cytokines. Preservation of beta-cell function is now gaining recognition as a critical target in the management of type 2 diabetes. For patients with frank type 2 diabetes, preservation of beta-cell function has the potential to reduce or stabilise the progression of type 2 diabetes and to decrease the need for additional oral glucose-lowering agents and/or insulin therapy. There is a growing body of animal/preclinical evidence for improved and preserved beta-cell function with current glucose-lowering agents, such as the thiazolidinediones, metformin and the glucagon-like peptide-1 analogue, exenatide. Clinical studies incorporating indirect measures of beta-cell function also support a protective effect with some agents. A number of novel therapies that are currently under investigation may also offer beta-cell structural and functional protection, including dipeptidyl peptidase IV inhibitors and cannabinoid receptor type 1 blockers. Emerging evidence from interventional trials suggests that both intensive lifestyle changes and pharmacotherapy can delay or possibly prevent the onset of type 2 diabetes in high-risk individuals. For patients newly diagnosed with type 2 diabetes, early and aggressive intervention strategies that combine maximal glucose-lowering efficacy alongside potential beta-cell preserving properties may provide an opportunity to delay or prevent progression of the disease.
Insights
Preserving beta-cell function is crucial for managing type 2 diabetes, as these cells progressively fail. Early interventions with glucose-lowering agents and lifestyle changes can slow disease progression.
Area of Science:
- Endocrinology
- Metabolic Diseases
- Pharmacology
Background:
- Type 2 diabetes is characterized by progressive loss of glycemic control due to beta-cell failure.
- Mechanisms of beta-cell dysfunction include glucotoxicity, lipotoxicity, insulin resistance, amyloid deposition, and altered cytokines.
- Preserving beta-cell function is a critical therapeutic target for managing type 2 diabetes.
Purpose of the Study:
- To review the evidence for preserving beta-cell function in type 2 diabetes management.
- To explore the role of existing and novel therapies in protecting beta-cells.
- To highlight the potential of early, aggressive interventions in delaying or preventing type 2 diabetes.
Main Methods:
- Review of preclinical and clinical studies on glucose-lowering agents.
- Examination of emerging therapies targeting beta-cell protection.
- Analysis of interventional trial data on lifestyle changes and pharmacotherapy.
Main Results:
- Preclinical evidence suggests thiazolidinediones, metformin, and exenatide can improve/preserve beta-cell function.
- Clinical studies indicate some agents may have a protective effect on beta-cells.
- Novel therapies like DPP-IV inhibitors and CB1 blockers show potential for beta-cell protection.
Conclusions:
- Preserving beta-cell function can stabilize type 2 diabetes progression and reduce treatment needs.
- Early and aggressive interventions combining glucose-lowering efficacy and beta-cell protection are promising.
- Intensive lifestyle changes and pharmacotherapy may delay or prevent type 2 diabetes onset in high-risk individuals.
Related Concept Videos
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Diabetes Mellitus: Type 2 and Gestational
Carbohydrate Metabolism
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in the...
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type I Diabetes II: Pathophysiology
Type II Diabetes I: Introduction
